Építés alatt – nem éles oldal
Belépés
Fut, nem toborozFázis nélkül

The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens

A legfontosabb adatok

Ki végzi
HOYA Lens Thailand LTD.
Hol
Kína5 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Fut, nem toboroz
Résztvevők
249 fő vett részt
Kezdés
2023. júl. 31.
Várható befejezés
2027. máj. 31.
A vizsgálat típusa
Beavatkozással járó, 3 csoport
A vizsgált kezelések
  • Model-A Novel spectacle lens
  • Model-B Novel spectacle lens
  • Single vision spectacle lens
A regiszteradat frissítve
2026. szeptember 18.

Ki vehet részt

Életkor
7 év – 13 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 20 feltétel megnézéseKevesebb

Ki vehet részt

  • Participant and parent (or guardian) are able and willing to provide consent
  • Participant and parent (or guardian) ensure to attend required study visits and adhere to participant requirements
  • Parent or guardian understands and accepts random allocation of grouping, and that participant and parent (or guardian) will not be told which group participant is allocated to
  • Participant willing to wear the study spectacles lens for a minimum of 12 hours per day for the duration of the study
  • Age at time of parent or guardian consent and participant assent: 7 - 13 years old
  • Spherical equivalent cycloplegic autorefraction: -1.00 to -7.00 D in each eye
  • Cycloplegic autorefraction astigmatism of 1.50 D or less in each eye
  • Cycloplegic autorefraction anisometropia of 1.50 D or less
  • Monocular best corrected distance visual acuity (BCDVA) equal to or better than logMAR 0.10 in each eye

Ki nem vehet részt

  • (a) Have received treatment of myopic control pharmaceutical medication (e.g., atropine) or light fundus illuminance therapy (e.g., repeated red light therapy) within 6 months prior to entry into this study. (b) Have received treatment of myopia control such as contact lenses, orthokeratology lenses etc., progressive addition lenses, bifocal lenses, within 3 months. (c) Have received treatment of myopia control such as defocus spectacle lenses (difference between both eye's non-cycloplegic autorefraction and lens-meter results of the respective lenses are equal or less than 0.50 D SER) etc. within one month prior to entry into this study
  • Participation in a clinical trial within 30 days prior to entry into this study or during participation
  • Previous intraocular surgery
  • Any medical treatment or medication which might have an influence on vision or interfere with study assessments
  • Participant is allergy to fluorescein, benoxinate, proparacaine, tropicamide or cyclopentolate eye drops
  • Medical history of binocular vision abnormalities
  • Participant who, in the judgment of the Investigator, presence of any emotional, physiologic, or anatomical condition which may preclude participation in this study or provide an inappropriate landscape for the intended study treatment
  • Any ocular and systemic abnormalities might be expected to affect visual functions or refractive development
  • Participant with clinically significant strabismus (including intermittent tropia)
  • Participant with amblyopia
  • Pathological myopia (myopia that leads to structural changes in the posterior segment of the eye including posterior staphyloma, myopic maculopathy, and high myopia-associated optic neuropathy)

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this clinical trial is to test Novel spectacle lenses in myopic children. The main question it aims to answer are: safety and efficacy of the lenses. Participants will be asked to wear spectacles and participate in eye exams and questionnaires. Researchers will compare Novel spectacle lenses and general single vision spectacle lenses to see if the Novel spectacle lenses correct myopic ametropia, slow the progression of myopia and axial elongation.

A vizsgálat 3 csoportja

  • Model-A Novel Spectacle lensA vizsgált kezelés
  • Model-B Novel Spectacle lensA vizsgált kezelés
  • Single Vision Spectacle lensEgyéb csoport

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2026. szeptember 18.